Cancer researchers, led by investigators at Vanderbilt-Ingram Cancer Center, have identified two novel gene fusions in melanoma that may be responsive to existing cancer therapies. Melanoma is the most deadly form of skin cancer.
A metabolic enzyme plays a crucial role in vascular development and may be a good target for cancer therapies.
The breast cancer drug tamoxifen improves cognitive performance in post-menopausal women.
The protein CK1 delays cell division to avoid the generation of defects that drive tumorigenesis.
A five-year study to explore new technologies that automate patient care outside of hospitals and doctors’ offices will identify ways technology can provide real-time feedback and guidance to patients and to alert care coordination teams before health issues escalate.
A protein kinase linked to inflammation and tumor development may be a good target for gastric cancer therapies.